INTRODUCTION: There have been contradictory data on whether or not BRAF V600E mutation should be regard as a poor prognosis predictor of papillary thyroid carcinoma (PTC). To settle down the conflict, this metaanalysis is prepared to clarify the present prognostic role of BRAF V600E mutation in patients with PTC. METHODS AND MATERIALS: The relevant published researches were incorporated according to the defined inclusion/exclusion criteria from PubMed. The effect sizes of outcome parameters were estimated by hazard ratios (HRs). RESULTS: The current meta-analysis included 19 researches with a total of 6087 patients. We have found that patients with BRAF V600E mutation have a poor overall survival (the pooled HR=2.91, 95% confidence interval (CI): 1.35-6.29). Furthermore, subgroup analysis of the recurrence-free survival (RFS) of PTC patients by races indicated that BRAF V600E mutation predicts poor RFS of patients (the pooled HR=1.63, 95% CI: 1.37-1.93), both Caucasian (the pooled HR=1.57, 95% CI: 1.30-1.90) and Asian (the pooled HR=1.91, 95% CI: 1.28-2.87). CONCLUSIONS: The poor prognosis predicted role of BRAF V600E mutation in PTC was certified from the current meta-analysis. The BRAF V600E mutation may be used as a prognostic predictor of patients with PTC.
INTRODUCTION: There have been contradictory data on whether or not BRAFV600E mutation should be regard as a poor prognosis predictor of papillary thyroid carcinoma (PTC). To settle down the conflict, this metaanalysis is prepared to clarify the present prognostic role of BRAFV600E mutation in patients with PTC. METHODS AND MATERIALS: The relevant published researches were incorporated according to the defined inclusion/exclusion criteria from PubMed. The effect sizes of outcome parameters were estimated by hazard ratios (HRs). RESULTS: The current meta-analysis included 19 researches with a total of 6087 patients. We have found that patients with BRAFV600E mutation have a poor overall survival (the pooled HR=2.91, 95% confidence interval (CI): 1.35-6.29). Furthermore, subgroup analysis of the recurrence-free survival (RFS) of PTC patients by races indicated that BRAFV600E mutation predicts poor RFS of patients (the pooled HR=1.63, 95% CI: 1.37-1.93), both Caucasian (the pooled HR=1.57, 95% CI: 1.30-1.90) and Asian (the pooled HR=1.91, 95% CI: 1.28-2.87). CONCLUSIONS: The poor prognosis predicted role of BRAFV600E mutation in PTC was certified from the current meta-analysis. The BRAFV600E mutation may be used as a prognostic predictor of patients with PTC.
Authors: Cleo Mesa; Mana Mirza; Norisato Mitsutake; Maureen Sartor; Mario Medvedovic; Craig Tomlinson; Jeffrey A Knauf; Georg F Weber; James A Fagin Journal: Cancer Res Date: 2006-07-01 Impact factor: 12.701
Authors: Debora L S Danilovic; Erika U Lima; Regina B Domingues; Lenine G Brandão; Ana O Hoff; Suemi Marui Journal: Eur J Endocrinol Date: 2014-03-13 Impact factor: 6.664
Authors: Mingzhao Xing; Ali S Alzahrani; Kathryn A Carson; Young Kee Shong; Tae Yong Kim; David Viola; Rossella Elisei; Bela Bendlová; Linwah Yip; Caterina Mian; Federica Vianello; R Michael Tuttle; Eyal Robenshtok; James A Fagin; Efisio Puxeddu; Laura Fugazzola; Agnieszka Czarniecka; Barbara Jarzab; Christine J O'Neill; Mark S Sywak; Alfred K Lam; Garcilaso Riesco-Eizaguirre; Pilar Santisteban; Hirotaka Nakayama; Roderick Clifton-Bligh; Giovanni Tallini; Elizabeth H Holt; Vlasta Sýkorová Journal: J Clin Oncol Date: 2014-10-20 Impact factor: 44.544
Authors: Shuiying Hu; Dingxie Liu; Ralph P Tufano; Kathryn A Carson; Eli Rosenbaum; Yoram Cohen; Elizabeth H Holt; Katja Kiseljak-Vassiliades; Kerry J Rhoden; Sara Tolaney; Stephen Condouris; Giovanni Tallini; William H Westra; Christopher B Umbricht; Martha A Zeiger; Joseph A Califano; Vasily Vasko; Mingzhao Xing Journal: Int J Cancer Date: 2006-11-15 Impact factor: 7.396
Authors: Julio C Ricarte-Filho; Mabel Ryder; Dhananjay A Chitale; Michael Rivera; Adriana Heguy; Marc Ladanyi; Manickam Janakiraman; David Solit; Jeffrey A Knauf; R Michael Tuttle; Ronald A Ghossein; James A Fagin Journal: Cancer Res Date: 2009-06-01 Impact factor: 12.701
Authors: Sandeep Kumar Parvathareddy; Abdul K Siraj; Saeeda O Ahmed; Felisa DeVera; Saif S Al-Sobhi; Fouad Al-Dayel; Khawla S Al-Kuraya Journal: Front Oncol Date: 2022-01-17 Impact factor: 6.244